Six different ROS1 fusion partners have already been described in pediatric CNS tumors (+/−7% of pediatric CNS tumors): GOPC, ARCN1, CHCHD3, ZCCHC8, TPR and CEP85L [2,23,24,25]. This evidence concerns the gene CHCHD3 and central nervous system neoplasm.